NASDAQ · ASMB
Assembly Biosciences, Inc.
$20.86+$0.29 (+1.41%)
Assembly Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.47% below the high.
Loading market information…
NASDAQ · ENTA · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Enanta Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.99% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Enanta Pharmaceuticals, Inc.’s next earnings report is currently expected on Nov 16, 2026, with estimated earnings per share of -$0.72. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Enanta Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2025 | May 12, 2025 | -$1.06-1.92% vs estimate | $14.93M-6.48% vs estimate |
|---|
| Q1 2025 | Feb 10, 2025 | -$1.05+9.48% vs estimate | $16.96M-1.68% vs estimate |
|---|
| Q4 2024 | Nov 25, 2024 | -$1.36-17.24% vs estimate | $67.64M+277.22% vs estimate |
|---|
THE ANALYST VIEW
19 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $20.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$20.86+$0.29 (+1.41%)
Assembly Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.47% below the high.
$3.14-$0.07 (-2.18%)
Nautilus Biotechnolgy, Inc.’s quoted price sits in the upper half of its reported 52-week range, 27.15% below the high.
$4.31+$0.04 (+0.94%)
Atea Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.18% below the high.
$4.02+$0.03 (+0.75%)
Immuneering Corporation’s quoted price sits in the lower half of its reported 52-week range, 52.59% below the high.
$4.10-$0.04 (-0.97%)
Prelude Therapeutics Incorporated’s quoted price sits in the upper half of its reported 52-week range, 39.97% below the high.
$2.09-$0.04 (-1.88%)
Foghorn Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.54% below the high.
$1.89-$0.09 (-4.55%)
Pyxis Oncology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 65.95% below the high.
$1.76-$0.08 (-4.35%)
Voyager Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.88% below the high.
